B. Braun Melsungen AG - Contract manufacturin
B. Braun OEM is your reliable partner for contract manufacturing of your drugs. Based on our profound experience, we manufacture and fill pharmaceuticals according to your needs.
B. Braun Melsungen AG - Contract manufacturing
If you are searching for a reliable partner for contract manufacturing of your drugs, B. Braun OEM is the pick of the bunch. Based on our profound experience, we manufacture and fill pharmaceuticals according to your needs.
At B. Braun OEM we offer contract manufacturing for infusion, irrigation and volume replacement solutions as well as standard injectables, anesthetics and dermatological products like creams, gels and pomades. Depending on the product requirements, we can fill in containers of different sizes, shapes and materials.
Benefit from our in-depth knowledge in the production of drugs from aqueous solutions to lipid emulsions. With our technologies we will meet your challenges concerning processes and packaging. We are able to produce standard and custom solutions in small and large volumes.
Depending on the requirements of your solution, we can offer the right container. The correct choice of material is made following stability and compatibility analysis. And it does not stop there –our broad range of medical devices acts as a complement to the entire drug application system.
Visit our booth no. 1H19 at the ICSE in Paris and learn more about contract manufacturing!
B. Braun Melsungen AG
OEM Division Europe
Carl-Braun-Straße 1
34212 Melsungen
Germany
Phone: +49 5661 71-0
Fax: +49 5661 71-3562
[email protected]http://www.bbraunoem.comwww.kitpacking-bbraun.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
